# Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

> **NCT00661713** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 1631 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** rMenB+OMV NZ
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00661713
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-04
- **Final completion:** 2010-12
- **Target enrollment:** 1631 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661713, "Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00661713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*